横浜市立大学　内分泌・糖尿病内科

2013-2017主要論文

2017年

  1. Takahashi K, Nakamura A, Miyoshi H, Nomoto H, Kameda H, Cho KY, Nagai S, Shimizu C, Taguri M, Terauchi Y, Atsumi T. Factors associated with an inadequate hypoglycemia in the insulin tolerance test in Japanese patients with suspected or proven hypopituitarism. Endocr J. 2017 64(4):387-392
  2. Seino Y, Terauchi Y, Wang X, Watanabe D, Niemoeller E; study investigators.. Safety, tolerability, and efficacy of lixisenatide as monotherapy in Japanese patients with type 2 diabetes mellitus: An open-label, multicenter study.J Diabetes Investig. 2017 Feb 13. doi: 10.1111/jdi.12646. [Epub ahead of print]
  3. Terauchi Y, Yamada Y, Ishida H, Ohsugi M, Kitaoka M, Satoh J, Yabe D, Shihara N, Seino Y. Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START-J trial).  Diabetes Obes Metab. 2017 Aug;19(8):1188-1192.
  4. Miya A, Nakamura A, Miyoshi H, Cho KY, Nagai S, Kurihara Y, Aoki S, Taguri M, Terauchi Y, Atsumi T. Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: a randomized controlled trial.J Diabetes Investig. 2017 Mar 10. doi: 10.1111/jdi.12654. [Epub ahead of print]
  5. Terauchi Y, Koyama M, Cheng X, Sumi M, Riddle MC, Bolli GB, Hirose T, on behalf of the EDITION JP 2 study group. Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral antihyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension)Diabetes Metabolism, in press, 2017.
  6. Terauchi Y, Tamura M, Senda M, Gunji R, Kaku K. Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial. Diabetes Obes Metab. 2017 Mar 30. doi: 10.1111/dom.12957. [Epub ahead of print] PubMed PMID:
    28371205.
  7. Terauchi Y, Kim YK, Tanaka T, Nanatani K, Takahashi T, Abe K. Asp30 of Aspergillus oryzae cutinase CutL1 is involved in the ionic interaction with fungal hydrophobin RolA. Biosci Biotechnol Biochem. 2017 Jul;81(7):1363-1368.
  8. Tajima K, Shirakawa J, Okuyama T, Kyohara M, Yamazaki S, Togashi Y, Terauchi Y. Effects of metformin on compensatory pancreatic β-cell hyperplasia in mice fed a high-fat diet. Am J Physiol Endocrinol Metab. 2017 May 16:ajpendo.00447.2016. doi: 10.1152/ajpendo.00447.2016. [Epub ahead of print] PubMed PMID: 28512156.
  9. Okuyama T, Shirakawa J, Yanagisawa H, Kyohara M, Yamazaki S, Tajima K, Togashi Y, Terauchi Y. Identification of the matricellular protein Fibulin-5 as a target molecule of glucokinase-mediated calcineurin/NFAT signaling in pancreatic islets. Sci Rep. 2017 May 24;7(1):2364.
  10. Shigematsu E, Yamakawa T, Oba MS, Suzuki J, Nagakura J, Kadonosono K, Terauchi Y. A Randomized Controlled Trial of Vildagliptin Versus Alogliptin: Effective Switch From Sitagliptin in Patients With Type 2 Diabetes. J Clin Med Res. 2017 Jul;9(7):567-572.
  11. Kawata T, Iizuka T, Iemitsu K, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyanagi S, Hoshino K, Ishikawa M, Matsuzawa Y, Obana M, Sasai N, Kaneshige H, Minagawa F, Saito T, Shinoda K, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I. Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus. J Clin Med Res. 2017 Jul;9(7):586-595.
  12. Tajima K, Shirakawa J, Togashi Y, Yamazaki S, Okuyama T, Kyohara M, Konishi H, Terauchi Y. Metabolic recovery of lipodystrophy, liver steatosis, and pancreatic β cell proliferation after the withdrawal of OSI-906. Sci Rep. 2017 Jun 23;7(1):4119.
  13. Aoki K, Nagakura M, Taguri M, Kamiyama H, Masumura M, Furuie T, Oka M, Kamiko K, Nakajima S, Akema N, Terauchi Y. Effect of Switching From an Anti-Diabetic Loose Dose Combination to a Fixed Dose Combination Regimen at Equivalent Dosage for 6 Months on Glycemic Control in Japanese Patients With Type 2 Diabetes: A Pilot Study. J Clin Med Res. 2017 Aug;9(8):719-724.
  14. Seino Y, Terauchi Y, Osonoi T, Yabe D, Abe N, Nishida T, Zacho J, Kaneko S. Safety and efficacy of semaglutide once weekly versus sitagliptin once daily, both as monotherapy in Japanese subjects with type 2 diabetes. Diabetes Obes Metab. 2017 Aug 8. doi: 10.1111/dom.13082. [Epub ahead of print] PubMed PMID: 28786547.
  15. Iemitsu K, Kawata T, Iizuka T, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyanagi S, Hoshino K, Ishikawa M, Matsuzawa Y, Obana M, Sasai N, Kaneshige H, Minagawa F, Saito T, Shinoda K, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I. Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study. J Clin Med Res. 2017 Sep;9(9):793-801.
  16. Minami T, Yamada M, Furuta R, Kamata K, Katsuragawa S, Terui S, Akiyama T, Yoshii T, Tsunoda T, Terauchi Y. Predicting the ability of elderly diabetic patients to acquire the insulin self-injection technique based on the number of animal names recalled. J Diabetes Investig. 2017 Aug 28. doi: 10.1111/jdi.12732. [Epub ahead of print] PubMed PMID: 28846204.
  17. Gonai M, Shigehisa A, Kigawa I, Kurasaki K, Chonan O, Matsuki T, Yoshida Y, Aida M, Hamano K, Terauchi Y. Galacto-oligosaccharides ameliorate dysbiotic Bifidobacteriaceae decline in Japanese patients with type 2 diabetes. Benef Microbes. 2017 Sep 8:1-12. doi: 10.3920/BM2016.0230. [Epub ahead of print] PubMed PMID: 28884590.
  18. Amagai M, Tsuchiya H, Chiba Y, Suzuki J, Nagakura J, Shigematsu E, Yamakawa T, Terauchi Y. Incretin Kinetics Before and After Miglitol in Japanese Patients With Late Dumping Syndrome. J Clin Med Res. 2017 Oct;9(10):879-885.
  19. Kyohara M, Shirakawa J, Okuyama T, Kimura A, Togashi Y, Tajima K, Hirano H, Terauchi Y. Serum Quantitative Proteomic Analysis Reveals Soluble EGFR To Be a Marker of Insulin Resistance in Male Mice and Humans. Endocrinology. 2017 Dec 1;158(12):4152-4164.
  20. Yamada E, Namiki Y, Takano Y, Takamine H, Inazumi K, Sasaki H, Yamada M, Ito S, Iwasaki T, Mantani N, Minami T, Osada UN, Terauchi Y, Nakajima A. Clinical factors associated with the symptoms of constipation in patients with diabetes mellitus: a multicenter study. J Gastroenterol Hepatol. 2017 Oct 19. doi: 10.1111/jgh.14022. [Epub ahead of print]
  21.  Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, Katsuyama H, Haraguchi M, Morita A, Ohashi K, Hara K, Morise A, Izumi K, Ishizuka N, Ohashi Y, Noda M, Kadowaki T; J-DOIT3 Study Group. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2017 Dec;5(12):951-964.

 2016年

  1. Orime K, Shirakawa J, Togashi Y, Tajima K, Inoue H, Nagashima Y, Terauchi Y. Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model. Eur J Pharmacol, 772: 22-32, 2016.
  2. Nagakura J, Yamakawa T, Taguri M, Tsuchiya H, Shigematsu E, Suzuki J, Morita S, Kadonosono K, Terauchi Y. Effects of exenatide and liraglutide on 24-hour glucose fluctuations in type 2 diabetes. Endocr J. 63(3): 239-47, 2016.
  3. Kamiyama H, Aoki K, Nakajima S, Shinoda K, Kamiko K, Taguri M, Terauchi Y. Effect of switching from sulphonylurea to repaglinide twice or three times daily for 4 months on glycemic control in Japanese patients with type 2 diabetes. Intern Med, in press, 2016.
  4. Terauchi Y, Yokote K, Nakamura I, Sugamori H. Safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): Interim results of a post-marketing surveillance study. Expert Opin Pharmacother. 17(4): 463-71, 2016.
  5. Goto A, Goto M, Terauchi Y, Yamaguchi N, Noda M. Association between severe hypoglycemia and cardiovascular disease risk in Japanese patients with type 2 diabetes. JAHA, 2016 Mar 9;5(3). pii: e002875.
  6. Shirakawa J, Okuyama T, Kyohara M, Yoshida E, Togashi Y, Tajima K, Yamazaki S, Kaji M, Koganei M, Sasaki H, Terauchi Y. DPP-4 inhibition improves early mortality, β cell function, and adipose tissue inflammation in db/db mice fed a diet containing sucrose and linoleic acid. Diabetes Metab Syndr. 2016 Mar 1;8:16.
  7. Shibata E, Aoki K, Tajima K, Taguri M, Terauchi Y. Comparison of efficacy and safety of taking miglitol dissolved in water during a meal and taking a miglitol tablet just before a meal in patients with type 2 diabetes. Expert Opin Pharmacother. 17(7): 889-94, 2016.
  8. Watanabe Y, Eto T, Taniguchi S, Terauchi Y. Risk of diabetes after 5 years among those with high-normal fasting plasma glucose Intern Med, in press, 2016.
  9. Aoki K, Tajima K, Taguri M, Terauchi Y. Effect of dehydroepiandrosterone (DHEA) on Akt and protein kinase C zeta (PKCζ) phosphorylation in different tissues of C57BL6, insulin receptor substrate (IRS)1-/-, and IRS2-/- male mice fed a high-fat diet. J Steroid Biochem Mol Biol. 2016 May;159:110-20.
  10. Iemitsu K, Iizuka T, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Kawata T, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyagi S, Hoshino K, Ishikawa M, Obana M, Sasai N, Kaneshige H, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I. Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study. J Clin Med Res. 2016 May; 8(5): 373-8.
  11. Togashi Y, Shirakawa J, Okuyama T, Kyohara M, Yamazaki S, Miyazawa A, Suzuki T, Hamada M, Terauchi Y. Evaluation of blood glucose meters for measuring mouse blood glucose levels. Scientific Reports, 2016 May 6;6:25465.
  12. Nezu Osada U, Sunagawa H, Asato T, Terauchi Y, Ueda S. A Common Susceptible Gene for Type 2 Diabetes is associated with Drug Response to DPP-4 inhibitor: Pharmacogenomic Cohort in Okinawa Japan. PLoS One. 2016 May 3;11(5):e0154821.
  13. Yuasa S, Sato K, Takai M, Ishikawa M, Umezawa S, Kubota A, Maeda H, Kanamori A, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I. Factor Analysis of Changes in Hemoglobin A1c After 12 Months of Sitagliptin Therapy in Patients With Type 2 Diabetes. J Clin Med Res. 2016 Jun;8(6):461-71.
  14. Noto H, Tanizawa Y, Aizawa T, Sone H, Yoshioka N, Terauchi Y, Inagaki N, Noda M. Cluster-randomized trial to improve the quality of diabetes management: The study for the efficacy assessment of the standard diabetes manual (SEAS-DM). J Diabetes Investig. 2015 Dec 12. doi: 10.1111/jdi.12455. [Epub ahead of print]
  15. Suzuki J, Yamakawa T, Nagakura J, Shigematsu E, Kadonososno K, Terauchi Y. Efficacy of switching from insulin glargine to insulin degludec in patients with type 1 diabetes: a 16-week retrospective study. Diabetology International . 2016 doi: 10.1007/s13340-016-0275-x [Epub ahead of print]
  16.  16.  Nakamura A, Iwami D, Miyoshi H, Morita K, Taguri M, Terauchi Y, Shinohara N, Atsumi T. Impact of renal transplantation on glucose tolerance in Japanese recipients with impaired glucose tolerance.Diabetic Med. 2016 Aug 9. doi:         0.1111/dme.13199.          [Epub      ahead of print]
  17. Yokote K, Terauchi Y, Nakamura I, Sugamori H. Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): Final results of a post-marketing surveillance study.     Dpert Opin       Pharmacother. 17(15): 1995-2003, 2016.
  18. Shirakawa J, Terauchi Y. Glucose- or insulin resistance-mediated β-cell replication: PKCζ integrates the proliferative signaling.J Diabetes Investig. 2016 Aug 1. doi: 10.1111/jdi.12558. [Epub ahead of print]
  19. Kubota N, Kubota T, Kajiwara E, Iwamura T, Kumagai H, Watanabe T, Inoue M, Takamoto I, Sasako T, Kumagai K, Kohjima M, Nakamuta M, Moroi M, Sugi K, Noda T, Terauchi Y, Ueki K, Kadowaki T. Differential hepatic distribution of insulin receptor    substrates causes selective insulin resistance in diabetes and obesity.Nature Communications 2016 Oct 6;7:12977. doi: 10.1038/ncomms12977.
  20. Kamiko K, Aoki K, Kamiyama H, Taguri M, Terauchi Y. Comparison of plasma glucose and gut hormone levels between drinking enteral formula over a period of 5 and 20 minutes in Japanese patients with type 2 diabetes: A pilot study.J Clin Med Res. 2016   Oct;8(10):749-52.
  21. Kubota T, Kubota N, Sato H, Inoue M, Kumagai H, Iwamura T, Takamoto I, Kobayashi T, Moroi M, Terauchi Y, Tobe K, Ueki K, Kadowaki T. Pioglitazone Ameliorates Smooth Muscle Cell Proliferation in Cuff-Induced Neointimal Formation by Both Adiponectin-Dependent and -Independent Pathways.Scientific Reports 2016 Oct 5;6:34707. doi: 10.1038/srep34707.
  22. Maruhashi T, Higashi Y, Kihara Y, Yamada H, Sata M, Ueda S, Odawara M, Terauchi Y, Dai K, Ohno J, Iida M, Sano H, Tomiyama H, Inoue T, Tanaka A, Murohara T, Node K; PROLOGUE Study Investigators. Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study.Cardiovasc Diabetol. 2016 Sep 13;15(1):134.
  23. Tsunoda T, Yamada M, Akiyama T, Minami T, Yoshii T, Kondo Y, Satoh S, Terauchi Y. The Effects of Ramelteon on Glucose Metabolism and Sleep Quality in Type 2 Diabetic Patients With Insomnia: A Pilot Prospective Randomized Controlled Trial.J Clin    Med  Res. 2016 Dec;8(12):878-887.

2015年

  1. Kamiko K, Aoki K, Kamiyama H, Taguri M, Shibata E, Ashiya Y, Minagawa F, Shinoda K, Nakajima S, Terauchi Y. Comparison of the administration of teneligliptin every day versus every other day in Japanese patients with type 2 diabetes: A randomized non-inferior test.J Clin Pharmacol. 55(2): 144-151, 2015.
  2. Nakamura A, Terauchi Y. Present status of clinical deployment of glucokinase activators. [Review]J Diabetes Invest, 6: 124-132, 2015.
  3. Inoue Y, Nakamura A, Kondo Y, Hamano K, Satoh S, Terauchi Y. A randomized controlled trial of liraglutide versus insulin detemir plus sitagliptin: effective switch from intensive insulin therapy to the once-daily injection in patients with well-controlled type 2 diabetes.J Clin Pharmacol, 55(7): 831-8, 2015.
  4. Nozaki Y, Fujita K, Wada K, Yoneda M, Kessoku T, Shinohara Y, Imajo K, Ogawa Y, Nakamuta M, Saito S, Masaki N, Nagashima Y, Terauchi Y, Nakajima A. Deficiency of iNOS-derived NO accelerates lipid accumulation-independent liver fibrosis in non-alcoholic steatohepatitis mouse model.BMC Gastroenterology, 15(1): 42, 2015.
  5. Maeda H, Kubota A, Kanamori A, Tanaka Y, Terauchi Y, Matsuba I, The Study Group of the Diabetes Committee, Kanagawa Physicians Association. Effects of sitagliptin on the serum creatinine in Japanese type 2 diabetes.Diabetes Res. Clin. Pract., 108(3):e42-5, 2015.
  6. Ishikawa M, Takai M, Maeda H, Kanamori A, Kubota A, Amemiya H, Iizuka T, Iemitsu K, Iwasaki T, Uehara G, Umezawa S, Obana M, Kaneshige H, Kaneshiro M, Kawata T, Sasai N, Saito T, Takuma T, Takeda H, Tanaka K, Tsurui N, Nakajima S, Hoshino K, Honda S, Machimura H, Matoba K, Minagawa F, Minami N, Miyairi Y, Mokubo A, Motomiya T, Waseda M, Miyakawa M, Naka Y, Terauchi Y, Tanaka Y, Matsuba I. Factors predicting therapeutic efficacy of combination treatment with sitagliptin and insulin in type 2 diabetic patients: The ASSIST-K Study.J Clin Med Res, 7(8):607-12, 2015.
  7. Takihata M, Nakamura A, Kondo Y, Kawasaki S, Kimura M, Terauchi Y. Comparison of azelnidipine and trichlormethiazide in Japanese type 2 diabetic patients with hypertension: the COAT randomized controlled trial.PloS ONE, 2015 May 4;10(5):e0125519.
  8. Inoue K, Goto A, Kishimoto M, Tsujimoto T, Yamamoto-Honda R, Noto H, Kajio H, Terauchi Y, Noda M. Possible discrepancy of HbA1c values and its assessment among patients with chronic renal failure, hemodialysis and other diseases.Clin Exp Nephrol. 2015 Apr 1. [Epub ahead of print]
  9. Kadowaki T, Haneda M, Inagaki N, Terauchi Y, Taniguchi A, Koiwai K, Rattunde H, Woerle HJ, Broedl UC. Efficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes: A randomized, double-blind, parallel-group study.Adv Ther. 32(4):306-18, 2015.
  10. Aoki K, Iijima T, Kamiyama H, Kamiko K, Terauchi Y. Anagliptin decreases serum lathosterol level in patients with type 2 diabetes: A pilot study.Expert Opin Pharmacother, 2015 Jun 22:1-6. [Epub ahead of print]
  11. Kaku K, Kadowaki T, Terauchi Y, Okamoto T, Sato A, Okuyama K, Juan Camilo Arjona Ferreira, Goldstein BJ. Sitagliptin improves glycemic excursion after a meal or after an oral glucose load in Japanese subjects with impaired glucose tolerance.Diabetes Obes Metab, 2015 Jun 12. doi: 10.1111/dom.12507. [Epub ahead of print]
  12. Umezawa  S, Kubota  A, Maeda  H, Kanamori  A, Matoba  K, Jin  Y, Minagawa  F, Obana  M, Iemitsu  K, Ito  S, Amamiya  H, Kaneshiro  M, Takai  M, Kaneshige  H, Hoshino  K, Ishikawa  M, Minami  N, Takuma  T, Sasai  N, Aoyagi  S, Kawata  T, Mokubo  A, Miyairi  Y, Takeda  H, Honda  S, Machimura  H, Motomiya  T, Waseda  M, Naka  Y, Tanaka  Y, Terauchi  Y, Matsuba  I. Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study.BMC Endocrine Disorders, 2015 Jul 3;15:34.
  13. Kondo Y, Satoh S, Nezu Osada U, Terauchi Y. Early liraglutide treatment improves β-cell function in patients with type 2 diabetes: A retrospective cohort study.Endocr J, in press, 2015.
  14. Yoshii T, Yamada M, Minami T, Tsunoda T, Sasaki M, Kondo Y, Satoh S, Terauchi Y. The effects of bazedoxifene on bone, glucose, and lipid metabolism in postmenopausal women with type 2 diabetes: An exploratory pilot study.J Clin Med Res, in press, 2015.
  15. Ono K, Nakamura A, Kawaguchi J, Takihata M, Inoue Y, Shirakawa J, Kameda A, Togashi Y, Hayashi T, Furuki T, Ito S, Takano T, Kawasaki S, Takeda H, Kaneko T, Kimura M, Mizushima S, Terauchi Y. The Safety, Efficacy and Treatment Satisfaction Comparison of Unchanged Premixed Insulin Regimen Plus Sitagliptin with Switch from the Premixed Insulin to Once-Daily Basal Insulin Plus Sitagliptin in Patients with Inadequately Controlled Type 2 Diabetes with Twice-Daily Premixed Insulin.Int J Diabetes Clin Res 2:4, 2015.
  16. Terauchi Y, Naito Y, Ikeda Y. Evaluation of unmet medical need among Japanese patients with type 2 diabetes mellitus and efficacy of Lixisenatide treatment among Asian type 2 diabetes mellitus patients.Diabetes Metab Syndr. 2015 Aug 22. pii: S1871-4021(15)00075-2.
  17. Emoto M, Terauchi Y, Ozeki A, Oura T, Takeuchi M, Imaoka T. A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial.Endocr. J., in press, 2015.
  18. Iizuka T, Iemitsu K, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Kawata T, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyagi S, Hoshino K, Ishikawa M, Matsuzawa Y, Obana M, Sasai N, Kaneshige H, Minagawa F, Saito T, Shinoda K, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I. Efficacy and Safety of Ipragliflozin in Japanese Patients with Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.J Clin Med Res, in press, 2015.
  19. Nakamura A, Mitsuhashi T, Takano Y, Miyoshi H, Kameda H, Nomoto H, Nagai S, Hatanaka Y, Shimizu C, Terauchi Y, Atsumi T. Usefulness of the octreotide test in Japanese patients for predicting the presence/absence of somatostatin receptor 2 expression in insulinomas.Endocr J. 2015 Nov 14. [Epub ahead of print]
  20. Komatsu Y, Nakamura A, Takihata M, Inoue Y, Yahagi S, Tajima K, Tsuchiya H, Takano T, Yamakawa T, Yoshida M, Miyoshi H, Terauchi Y. Safety and tolerability of diazoxide in Japanese patients with hyperinsulinemic hypoglycemia.Endocr J. 2015 Nov 20. [Epub ahead of print]
  21. Ito Y, Shibuya M, Hosokawa S, Motoki Y, Nagata R, Konishi H, Miyazaki T, Matsunaga T, Nomura Y, Mihara T, Ito S, Sugiura K, Terauchi Y. Indicators of the need for insulin treatment and the effect of treatment for gestational diabetes on pregnancy outcomes in Japan.Endocr J. 2015 Nov 25. [Epub ahead of print]
  22. Terauchi Y, Koyama M, Cheng X, Takahashi Y, Riddle MC, Bolli GB, Hirose T. New insulin glargine 300 U/mL versus glargine 100 U/mL in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drug(s): glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2).Diabetes Obes Metab, 2015 Dec 11. doi: 10.1111/dom.12618. [Epub ahead of print]
  23. Okamoto Y, Yamakawa T, Terauchi Y. Aging may affect insulin action independent of adiposity in non-diabetic subjects. [Review]J Atheroscler Thromb. 2015 Dec 19. [Epub ahead of print]
  24. Nozaki Y, Fujita K, Wada K, Yoneda M, Shinohara Y, Imajo K, Ogawa Y, Kessoku T, Nakamuta M, Saito S, Masaki N, Nagashima Y, Terauchi Y, Nakajima A. Deficiency of eNOS exacerbates early-stage NAFLD pathogenesis by changing the fat distribution BMC Gastroenterol. 2015 Dec 17;15(1):177.

2014年

  1. Kondo Y, Hamai J, Nezu U, Shigematsu E, Kamiko K, Yamazaki S, Takahashi M, Takano T, Kawasaki S, Yamada M, Yamakawa T, Terauchi Y. Second-line    treatments   in   dyslipidemic patients at risk of cardiovascular disease.Endocr J, 61(4): 343-51, 2014.
  2. Togashi Y, Shirakawa J, Orime K, Kaji M, Sakamoto E, Tajima K, Inoue H, Nakamura A, Tochino Y, Goshima Y, Shimomura I, Terauchi Y. β cell proliferation after a partial pancreatectomy is independent of IRS-2 in mice.Endocrinology, 155(5), 1643-52.2014.
  3. Shirakawa J, Terauchi Y. Selective and sequential loss of transcriptional factors: a hallmark of β cell failure in type 2 diabetes? Diabetes Invest, 5(4):359-61, 2014. [Review]
  4. Yamakawa T, Ogihara K, Utsunomiya H, Muraoka T, Kadonosono K, Terauchi Y. Colestimide improve glycemic control via hepatic glucose production in db/db mice.Endocr J, 61(5): 425-36, 2014.
  5. Takai M, Ishikawa M, Maeda H, Kanamori A, Kubota A, Amemiya H, Iizuka T, Iemitsu K, Iwasaki T, Uehara G, Umezawa S, Obana M, Kaneshige H, Kaneshiro M, Kawata T, Sasai N, Saito T, Takuma T, Takeda H, Tanaka K, Tsurui N, Nakajima S, Hoshino K, Honda S, Machimura H, Matoba K, Minagawa F, Minami N, Miyairi Y, Mokubo A, Motomiya T, Waseda M, Miyakawa M, Naka Y, Terauchi Y, Tanaka Y, Matsuba I. Safety and efficacy of adding sitagliptin to insulin in patients with type 2 diabetes: The ASSIST-K study.Diabetes Res Clin Pract. 103(3): e30-3, 2014.
  6. Tanizawa Y, Kaku K, Araki E, Tobe K, Terauchi Y, Utsunomiya K, Iwamoto Y, Watada H, Ohtsuka W, Watanabe D, Suganami H; for the Tofogliflozin 004 and 005 Study group. Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials.Expert Opin Pharmacother. 15(6):749-66, 2014.
  7. Kawata T, Kanamori A, Kubota A, Maeda H, Amamiya H, Takai M, Kaneshige H, Minagawa F, Iemitsu K, Kaneshiro M, Ishikawa M, Takeda H, Takuma T, Mokubo A, Machimura H, Obana M, Miyakawa M, Naka Y, Suzuki D, Terauchi Y, Toyoda M, Tanaka Y, Matsuba I. Is a switch from insulin therapy to liraglutide possible in Japanese type 2 diabetes mellitus patients?J Clin Med Res. 6(2):138-44, 2014.
  8. Shirakawa J, Okuyama T, Yoshida E, Shimizu M, Horigome Y, Tuno T, Hayasaka M, Abe S, Fuse M, Togashi Y, Terauchi Y. Effects of the antitumor drug OSI-906, a dual inhibitor of IGF-1 receptor and insulin receptor, on the glycemic control, β cell functions, and β cell proliferation in male miceEndocrinology, 155(6): 2102-11, 2014.
  9. Inoue K, Tsujimoto T, Yamamoto-Honda R, Goto A, Kishimoto M, Noto H, Kajio H, Doi S, Miyazaki S, Terauchi Y, Noda M. A newer conversion equation for the correlation between HbA1c and glycated albumin.Endocr J. 61(6): 553-60, 2014.
  10. Kaku K, Watada H, Iwamoto Y, Utsunomiya K, Terauchi Y, Tobe K, Tanizawa Y, Araki E, Ueda M, Suganami H, Watanabe D. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study.Cardiovasc Diabetol. 28;13(1): 65, 2014.
  11. Kamiyama H, Aoki K, Nakajima S, Shinoda K, Kamiko K, Taguri M, Terauchi Y. Effect of repaglinide therapy administered twice or thrice daily for 3 months on glycemic control in Japanese patients with type 2 diabetes.J Int Med Res. 42(5):1150-60, 2014.
  12. Terauchi Y, Satoi Y, Takeuchi M, Imaoka T. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study.Endocr. J. 61(10):949-59, 2014.
  13. Kadowaki T, Haneda M, Inagaki N, Terauchi Y, Taniguchi A, Koiwai K, Rattunde H, Woerle HJ, Broedl UC. Empagliflozin Monotherapy in Japanese Patients with Type 2 Diabetes Mellitus: a Randomized, 12-Week, Double-Blind, Placebo-Controlled, Phase II Trial.Adv Ther. 31(6): 621-38, 2014.
  14. Miyazaki Y, Yusa T, Matsuo S, Terauchi Y, Miyazaki S. Zyxin modulates the transmigration of Haemophilus influenzae to the central nervous system.Virulence. 5(6): 665-72, 2014.
  15. Shirakawa J, Murohashi Y, Okazaki N, Yamazaki S, Tamura T, Okuyama T, Togashi Y, Terauchi Y. Using miglitol at 30 min before meal is effective in hyperinsulinemic hypoglycemia after a total gastrectomy.Endocr. J. 61(11): 1115-23, 2014.
  16. Sato K, Satoh S, Muraoka T, Miyazaki Y, Kikuchi K, Terauchi Y. Evidence of brain atrophy detected on magnetic resonance imaging is associated with failure of acquisition of the ability for insulin self-injection. Endocr. J. 61(11): 1125-30, 2014.
  17. Shigematsu E, Yamakawa T, Kadonosono K, Terauchi Y. Effect of sitagliptin on lipid profile in patients with type 2 diabetes mellitus. J Clin Med Res. 6(5): 327-35, 2014.
  18. Kamiko K, Aoki K, Kamiyama H, Taguri M, Shibata E, Ashiya Y, Minagawa F, Shinoda K, Nakajima S, Terauchi Y. Comparison of the administration of teneligliptin every day versus every other day in Japanese patients with type 2 diabetes: A randomized non-inferior test.J Clin Pharmacol. 2014 Aug 27. doi: 10.1002/jcph.385. [Epub ahead of print]
  19. Nakamura A, Yoneda M, Sumida Y, Miyoshi H, Nakajima A, Atsumi T, Terauchi Y. A caution in the use of the NAFIC scoring system as a diagnostic screening tool for nonalcoholic steatohepatitis.Gastrointestinal Digestive System. in press, 2014.
  20. Nakamura A, Terauchi Y. Present status of clinical deployment of glucokinase activators.J Diabetes Investig. in press, 2014. [Review]

2013年

  1. Takihata M, Nakamura A, Tajima K Komatsu Y, Tamura H, Yamazaki S, Kondo Y, Yamada M, Kimura M, Terauchi Y. Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial.Diabetes Obes. Metab., 15(5): 455-62, 2013.
  2. Maeda H, Kubota A, Kanamori A, Tanaka Y, Terauchi Y, Matsuba I. ASSET-K Study Group. Long-term efficacy and safety of sitagliptin in the treatment of Japanese type 2 diabetes (ASSET-K1) to a target of HbA1c <7%. J Endocrinol Invest, 36(8): 568-73, 2013.
  3. Ishii H, Terauchi Y, Jinnouchi H, Taketsuna M, Tsuji I, Takeuchi M. Effects of insulin changes on quality of life and glycaemic control in Japanese patients with type 2 diabetes mellitus: the INSIGHTs observational study. J Diabetes Invest, in press, 2013.
  4. Masuda K, Aoki K, Kamiko K, Takihata M, Ito Y, Nagakura M, Kawasaki S, Akema N, Hasegawa M, Nakajima S, Toumura S, Tsunoda S, Enomoto H, Shimotomai H, Terauchi Y. Glycemic control after addition of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes showing inadequate response to thrice-a day treatment with a-glucosidase inhibitors. Expert Opinion on Pharmacotherapy, 14(9):1111-8, 2013.
  5. Goto A, Morita A, Goto M, Sasaki S, Miyachi M, Aiba N, Kato M, Terauchi Y, Noda M, Watanabe S; for the Saku cohort Study Group. Validity of diabetes self-reports in the Saku Diabetes Study. J Epidemiology, 23(4):295-300, 2013.
  6. Kondo Y, Satoh S, Nagakura J, Kimura M, Nezu U, Terauchi Y. Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetesJ Diabetes Invest, in press, 2013.
  7. Nakamura A, Yoneda M, Sumida Y, Eguchi Y, Fujii H, Hyogo H, Ono M, Suzuki Y, Kawaguchi T, Aoki N, Okanoue T, Nakajima A, Maeda S, Terauchi Y. Modification of a simple clinical scoring system as a diagnostic screening tool for nonalcoholic steatohepatitis in Japanese patients with nonalcoholic fatty liver disease.J Diabetes Invest, in press, 2013.
  8. Tajima K, Shirakawa J, Togashi Y, Inoue H, Sato K, Orime K, Ito Y, Kaji M, Sakamoto E, Nakamura A, Aoki K, Goshima Y, Atsumi T, Terauchi Y. AMPK is involved in the regulation of incretin receptors expression in pancreatic islets under a low glucose concentration.PLoS One. 2013 May 22;8(5):e64633. doi: 10.1371/journal.pone.0064633.
  9. Masuda K, Kawaguchi J, Aoki K, Yamakawa T, Matsuba I, Terauchi Y. Effect of instruction on caloric intake (25 or 30 kcal/ kg [ideal body weight]/ day) on the degree of glycemic control and improvement of lipid profile in obese patients with type 2 diabetes: a prospective, randomized, controlled, multicenter study (25 or 30 study).J Clin Med Res, 5(5): 368-75, 2013.
  10. Shirakawa J, Togashi Y, Sakamoto E, Kaji M, Tajima K, Orime K, Inoue H, Kubota N, Kadowaki T, Terauchi Y. Glucokinase activation ameliorates ER stress-induced apoptosis in pancreatic β cells.Diabetes, 62(10): 3448-58, 2013.
  11. Goto M, Goto A, Morita A, Deura K, Sasaki S, Aiba N, Shimbo T, Terauchi Y, Miyachi M, Noda M, Watanabe S; Saku Cohort Study Group. Low-molecular-weight adiponectin and high-molecular-weight adiponectin levels in relation to diabetes.Obesity (Silver Spring). 2013 Jul 1. doi: 10.1002/oby.20553. [Epub ahead of print]
  12. Goto A, Arah OA, Goto M, Terauchi Y, Noda M, Severe Hypoglycaemia and Cardiovascular Disease: A Systematic Review and Meta-Analysis with Bias Analysis.BMJ, Jul 29;347:f4533. doi: 10.1136/bmj.f4533.
  13. Zolzaya K, Nakamura A, Tajima K, Terauchi Y. Role of insulin receptor substrate-1 for diethylnitrosamine plus high-fat diet-induced hepatic tumorigenesis in mice.J Diabetes Invest, in press, 2013
  14. Takihata M, Nakamura A, Aoki K, Kimura M, Sekino Y, Inamori M, Maeda S, Gotoh E, Nakajima A, Terauchi Y. Comparison of intragastric balloon therapy and intensive lifestyle modification therapy with respect to weight reduction and abdominal fat distribution in super-obese Japanese patients.Obes Res Clin Pract, in press, 2013.
  15. Tajima K, Nakamura A, Shirakawa J, Togashi Y, Orime K, Sato K, Inoue H, Kaji M, Sakamoto E, Ito Y, Aoki K, Nagashima Y, Atsumi T, Terauchi Y. Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 Mice.Am. J. Physiol. Endocrinol. Metab., 305(8): E987-98, 2013.
  16. Kawata T, Kanamor A, Kubota A, Maeda H, Matoba K, Jin Y, Ito S, Amamiya H, Takai M, Kaneshige H, Minami N, Minagawa F, Iemitsu K, Kaneshiro M, Hoshino K, Ishikawa M, Takeda H, Motomiya T, Takuma T, Aoyagi S, Mokubo A, Machimura H, Obana M, Miyakawa M, Naka Y, Terauchi Y, Toyoda M, Suzuki D, Tanaka Y, Matsuba I. Clinical Effects of Liraglutide on Diabetes Control in Japanese Type 2 Diabetes Mellitus Patients. Diabetology International, in press
  17. Orime K, Shirakawa J, Togashi Y, Tajima K, Inoue H, Ito Y, Sato K, Nakamura A, Aoki K, Goshima Y, Terauchi Y. Trefoil factor 2 promotes cell proliferation in pancreatic β cells through CXCR-4-mediated ERK1/2 phosphorylation.Endocrinology, 154(1): 54-64, 2013.
  18.  Nakamura A, Terauchi Y. Lessons from mouse models of high-fat diet-induced NAFLD.Int J Med Sci, 14(11):21240-57, 2013.
  19. Kawasaki S, Misawa H, Tamura Y, Kondo Y, Satoh S, Hasegawa O, Kato S, Terauchi Y. Relationship between Coronary Artery Disease and Retinopathy in Patients with Type 2 Diabetes Mellitus.Intern Med, 52(22): 2483-7, 2013.
  20. Ono K, Yamasue K, Tochikubo O, Terauchi Y, Mizushima S. Lifestyle modification system with use of earphone-type thermometer, ABPM and wrist-type pulse rate recorder.Clin Exp Hypertens, in press, 2013.
  21. Aoki K, Kamiyama H, Masuda K, Kamiko K, Noguchi Y, Tajima K, Terauchi Y. Effects of miglitol, vildagliptin, or their combination on serum insulin and peptide YY levels and plasma glucose, cholecystokinin, ghrelin, and obestatin levels.Endocr J, in press, 2013.
  22. Nakamura A, Hagiwara E, Hamai J, Taguri M, Terauchi Y. Impact of underlying diabetes and the presence of cavity on the treatment outcomes in patients with pulmonary tuberculosis.Diabetic Medicine, in press, 2013.
  23. Kato S, Fukui K, Kawaguchi J, Ishii N, Koga M, Kusakawa Y, Kusama I, Nakachi T, Nakagawa T, Terauchi Y, Uchino K, Kimura K, Umemura S. Relationship between coronary flow reserve evaluated by phase-contrast cine cardiovascular magnetic resonance and serum eicosapentaenoic acid.J Cardiovasc Magn Reson. 2013 Dec 20;15(1):106.